Novel treatments are urgently needed for meningiomas progressing after local therapies (surgery, radiotherapy). So far, no effective systemic therapies are known in this situation. The LUMEN-1 trial will investigate in a prospective randomized trial the efficacy of the precision medicine "theranostic" concept of combining diagnostic patient selection using PET-based molecular imaging and target-specific therapeutic intervention using a systemically administered radioligand.
The rationale for the LUMEN-1 trial is based on the following: (a) high somatostatin receptor (SSTR) expression in meningiomas, (b) wide-spread availability of clinically established SSTR-PET imaging, (c) proven efficacy of SSTR-targeting radioligand therapy using [177Lu]Lu-DOTATATE in another tumor type (neuroendocrine tumors), and (d) promising experiences with [177Lu]Lu-DOTATATE therapy in compassionate use applications and retrospective case series and interim results from one ongoing uncontrolled prospective trial in meningiomas. LUMEN-1 is the first randomized clinical trial to investigate [177Lu]Lu-DOTATATE therapy in refractory meningioma and may open new avenues for treatment and research in this area.

开始日期2024-11-06

申办/合作机构

Eortc

[+1]

NCT05687123 / Recruiting临床1期IIT

A Phase I Dose Escalation-Expansion Trial of Sunitinib Malate Plus Lutetium Lu 177 Dotatate (Lutathera) in Somatostatin Receptor Positive Pancreatic Neuroendocrine Tumors

This phase I trial tests the safety, side effects, and best dose of sunitinib malate in combination with lutetium Lu 177 dotatate in treating patients with pancreatic neuroendocrine tumors. Sunitinib malate is in a class of medications called kinase inhibitors and a form of targeted therapy that blocks the action of abnormal proteins called VEGFRs that signal tumor cells to multiply. This helps stop or slow the spread of tumor cells. Radioactive drugs, such as lutetium Lu 177 dotatate, may carry radiation directly to tumor cells and not harm normal cells. It is also a form of targeted therapy because it works by attaching itself to specific molecules (receptors) on the surface of tumor cells, known as somatostatin receptors, so that radiation can be delivered directly to the tumor cells and kill them. Giving sunitinib malate and lutetium Lu 177 dotatate in combination may be safer and more effective in treating pancreatic neuroendocrine tumors than giving either drug alone.

开始日期2024-07-04

申办/合作机构

National Cancer Institute

NCT06379217 / Not yet recruiting临床1期

A Phase I, Open-label, Multi-center Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.

The purpose of this study is to evaluate the change in the expression of treatment targets on the surface of tumor cells (Prostate Specific Membrane Antigen (PSMA), Somatostatin Receptor 2 (SSTR2), and Gonadotropin Releasing Hormone Receptor (GRPR)) between the start and after the completion of radioligand therapy (RLT). Study will use radioligand imaging (RLI) to determine predominantly expressed target on the surface of tumor cells. Based on predominant expression of target, corresponding RLT targeting PSMA, SSTR2, or GRPR RLT will be given for up to 6 cycles every 6 weeks as intravenous (i.v.) injection in participants with metastatic neuroendocrine prostate cancer (mNEPC).

开始日期2024-06-18

申办/合作机构

Novartis Pharmaceuticals Corp.

100 项与 (177镥)镥氧奥曲肽相关的临床结果

登录后查看更多信息

100 项与 (177镥)镥氧奥曲肽相关的转化医学

登录后查看更多信息

100 项与 (177镥)镥氧奥曲肽相关的专利（医药）

登录后查看更多信息

987

项与 (177镥)镥氧奥曲肽相关的文献（医药）

2106-07-05·Oncotarget

The impact of 177Lu-octreotide therapy on 99mTc-MAG3 clearance is not predictive for late nephropathy

Article

作者: Lapa, Constantin ; Bluemel, Christina ; Hänscheid, Heribert ; Lassmann, Michael ; Beykan, Seval ; Herrmann, Ken ; Lückerath, Katharina ; Werner, Rudolf A. ; Weich, Alexander ; Buck, Andreas K. ; Higuchi, Takahiro ; Scheurlen, Michael

Peptide Receptor Radionuclide Therapy (PRRT) for the treatment of neuroendocrine tumors may lead to kidney deterioration. This study aimed to evaluate the suitability of 99mTc-mercaptoacetyltriglycine (99mTc--MAG3) clearance for the early detection of PRRT-induced changes on tubular extraction (TE). TE rate (TER) was measured prior to 128 PRRT cycles (7.6±0.4 GBq 177Lu-octreotate/octreotide each) in 32 patients. TER reduction during PRRT was corrected for age-related decrease and analyzed for the potential to predict loss of glomerular filtration (GF). The GF rate (GFR) as measure for renal function was derived from serum creatinine. The mean TER was 234 ± 53 ml/min/1.73 m² before PRRT (baseline) and 221 ± 45 ml/min/1.73 m² after a median follow-up of 370 days. The age-corrected decrease (mean: -3%, range: -27% to +19%) did not reach significance (p=0.09) but significantly correlated with the baseline TER (Spearman p=-0.62, p<0.001). Patients with low baseline TER showed an improved TER after PRRT, high decreases were only observed in individuals with high baseline TER. Pre-therapeutic TER data were inferior to plasma creatinine-derived GFR estimates in predicting late nephropathy. TER assessed by 99mTc-MAG3-clearance prior to and during PRRT is not suitable as early predictor of renal injury and an increased risk for late nephropathy.

2024-02-01·European Journal of Nuclear Medicine and Molecular Imaging

The cycle effect quantified: reduced tumour uptake in subsequent cycles of [177Lu]Lu-HA-DOTATATE during peptide receptor radionuclide therapy

Article

作者: de Wit-van der Veen, B J ; Hendrikx, J J M A ; Siebinga, H ; Huitema, A D R ; de Vries-Huizing, D M V

BACKGROUND:

Clear evidence regarding the effect of reduced tumour accumulation in later peptide receptor radionuclide therapy (PRRT) cycles is lacking. Therefore, we aimed to quantify potential cycle effects for patients treated with [¹⁷⁷Lu]Lu-HA-DOTATATE using a population pharmacokinetic (PK) modelling approach.

METHODS:

A population PK model was developed using imaging data from 48 patients who received multiple cycles of [¹⁷⁷Lu]Lu-HA-DOTATATE. The five-compartment model included a central, kidney, spleen, tumour and lumped rest compartment. Tumour volume and continued use of long-acting somatostatin analogues (SSAs) were tested as covariates in the model. In addition, the presence of a cycle effect was evaluated by relating the uptake rate in a specific cycle as a fraction of the (tumour or organ) uptake rate in the first cycle.

RESULTS:

The final PK model adequately captured observed radioactivity accumulation in kidney, spleen and tumour. A higher tumour volume was identified to increase the tumour uptake rate, where a twofold increase in tumour volume resulted in a 2.3-fold higher uptake rate. Also, continued use of long-acting SSAs significantly reduced the spleen uptake rate (68.4% uptake compared to SSA withdrawal (10.5% RSE)). Lastly, a cycle effect was significantly identified, where tumour uptake rate decreased to 86.9% (5.3% RSE) in the second cycle and even further to 79.7% (5.6% RSE) and 77.6% (6.2% RSE) in the third and fourth cycle, respectively, compared to cycle one.

CONCLUSIONS:

Using a population PK modelling approach, the cycle effect of reduced tumour uptake in subsequent PRRT cycles was quantified. Our findings implied that downregulation of target receptors is probably not the major cause of the cycle effect, due to a plateau in the decrease of tumour uptake in the fourth cycle.

2024-02-01·European Journal of Nuclear Medicine and Molecular Imaging

p53 stabilisation potentiates [177Lu]Lu-DOTATATE treatment in neuroblastoma xenografts

Article

作者: Gago, Fernando Jose Ferrer ; Salomonsson, Sara Lundsten ; Mohajershojai, Tabassom ; Lane, David P ; Nestor, Marika ; Berglund, Hanna

Abstract:

Purpose:

Molecular radiotherapy is a treatment modality that is highly suitable for targeting micrometastases and [177Lu]Lu-DOTATATE is currently being explored as a potential novel treatment option for high-risk neuroblastoma. p53 is a key player in the proapoptotic signalling in response to radiation-induced DNA damage and is therefore a potential target for radiosensitisation.

Methods:

This study investigated the use of the p53 stabilising peptide VIP116 and [177Lu]Lu-DOTATATE, either alone or in combination, for treatment of neuroblastoma tumour xenografts in mice. Initially, the uptake of [177Lu]Lu-DOTATATE in the tumours was confirmed, and the efficacy of VIP116 as a monotherapy was evaluated. Subsequently, mice with neuroblastoma tumour xenografts were treated with placebo, VIP116, [177Lu]Lu-DOTATATE or a combination of both agents.

Results:

The results demonstrated that monotherapy with either VIP116 or [177Lu]Lu-DOTATATE significantly prolonged median survival compared to the placebo group (90 and 96.5 days vs. 50.5 days, respectively). Notably, the combination treatment further improved median survival to over 120 days. Furthermore, the combination group exhibited the highest percentage of complete remission, corresponding to a twofold increase compared to the placebo group. Importantly, none of the treatments induced significant nephrotoxicity. Additionally, the therapies affected various molecular targets involved in critical processes such as apoptosis, hypoxia and angiogenesis.

Conclusion:

In conclusion, the combination of VIP116 and [177Lu]Lu-DOTATATE presents a promising novel treatment approach for neuroblastoma. These findings hold potential to advance research efforts towards a potential cure for this vulnerable patient population.

280

项与 (177镥)镥氧奥曲肽相关的新闻（医药）

2024-05-03

·药时代

火热核药赛道又出并购交易！诺华以17.5亿美元收购Mariana Oncology

2024年5月2日，全球制药巨头诺华制药官宣了最新的一笔收购交易。诺华将收购核药初创公司 Mariana Oncology，首付款为10亿美元，预定里程碑付款为7.5亿美元。这一收购有望进一步巩固诺华在放射性配体疗法（radioligand therapies，RLTs）领域的布局和地位。诺华对ADC进行战略性弱化，而重兵主攻RDC，而且成为该领域的王者，目前已经上市两款核药，分别是Lutathera和Pluvicto。2016年以来，全球已有11款RDC药物获批上市，其中5款药物出自诺华，且诺华的Lutathera和Pluvicto是唯一2款用于治疗目的的RDC药物。 Lutathera于2018年1月26日被FDA批准上市，用于治疗生长抑素受体（SSTR）阳性的胃肠胰神经内分泌肿瘤患者。上市首年销售额达到了1.67亿美元，2019年增长到4.41亿美元，2022年营收为4.71亿美元，2023年销售额增长至6.05亿美元。 Pluvicto上市以来，销售表现屡超预期，势头超过了Lutathera。2022年上市后首年全球销售额达2.71亿美元，2023年上半年销售额4.51亿美元，2023年全年销售额跃升至9.80亿美元，离“重磅炸弹药物”只有一步之遥。这两款药物在2024年第一季度带来了总计4.79亿美元的收入。它们的出色表现促使资本市场对核药生物技术公司青睐有加。上个月Lutathera还获批用于治疗青少年患者，诺华也计划进一步扩大Pluvicto的适应症范围，将前列腺癌纳入其中。就在两天前，诺华扩大了与PeptiDream在放射治疗新药发现方面的合作。这是两家公司于2019年达成的多肽偶联药物（PDC）合作基础上的进一步扩展。 PeptiDream公司将利用其独有的多肽发现平台系统（PDPS），根据诺华指定的靶点，发现和优化创新大环肽。这些大环肽可能用于与放射性配体偶联，或者应用于其它治疗和诊断用途。基于合作协议，PeptiDream将获得1.8亿美元前期付款，并有资格获得高达27.1亿美元的开发、监管和商业化里程碑付款。诺华希望巩固其在该领域的未来地位，因为这个炙手可热的赛道已经成为MNC兵家必争之地，各家企业纷纷出手，完成大手笔交易。百时美施贵宝（BMS）斥资41亿美元收购RayzeBio，礼来斥资14亿美元收购POINT Biopharma，阿斯利康20亿美元收购Fusion Pharmaceuticals。这至少是诺华制药2024年迄今为止的第四次收购，之前的被收购公司包括炎症性疾病初创公司IFM Due、自身免疫生物技术公司Calypso和长期合作伙伴MorphoSys。通过收购Mariana，诺华制药获得了针对各种实体肿瘤的基于肽的放射治疗药物管线以及一个制造设施。Mariana的主要放射配体疗法，MC-339，预计将在今年下半年进入小细胞肺癌的人体研究。关于这笔交易，双方都非常看好，给予了积极的评价。诺华制药生物医学研究全球肿瘤学负责人Shiva Malek博士在接受Endpoints News采访时表示：因为诺华内部有一个重要的RLT研发管线，我们努力主动地，深思熟虑地而且果断地决定我们在该领域的下一步。 Mariana Oncology公司首席执行官Simon Read博士表示：这是一个非常激动人心的机会，有这样一个合作伙伴加入，可以扩大我们的药物在临床中的影响。该交易已经获得了联邦贸易委员会的批准，有望在本周五，也就是2024年5月3日，完成。诺华制药和Mariana的高级管理层将组成一个联合指导委员会，对后者进行“轻触式整合”，以保持生物技术公司的灵活性和动力。预计Mariana的大约70名员工都将继续留在公司。他还透露，与诺华的对话始于今年1月的摩根大通医疗保健会议。位于马萨诸塞州的Mariana Oncology成立于2021年，由三家著名生命科学风险投资公司Atlas Venture、RA Capital和Access Biotechnology共同孵化设立，是一家全面整合的下一代放射性药物研发公司，专注于开创一类基于肽分子的新型靶向放射性药物。 2023年9月7日，这家临床前生物技术公司宣布完成1.75亿美元的B轮融资。本轮融资由Deep Track和Forbion共同领投，Atlas Venture、Access Biotechnology、RA Capital、Nextech Invest、Surveyor Capital、礼来跟投。这次收购对Mariana的股东来说是一次巨大的投资回报。根据风险投资数据公司PitchBook的数据，这家初创公司在B轮融资时的估值为3.13亿美元。这意味着B轮融资后仅仅8个月公司就被收购，不紧让人立即想到了前不久刷屏的另一笔收购交易，普方生物被Genmab收购。 2024年4月3日下午，ADC公司普方生物宣布，公司将被丹麦生物技术公司Genmab收购，收购价格为18亿美元（约合130亿元人民币）。被收购前，普方生物刚刚在2024年2月完成了1.12亿美元超额B轮融资，用于加速其ADC管线的开发。关于普方生物是否是中国biotech，业界有不同的看法。有一点可以肯定的是：对于优质公司的投资，该出手时就出手，否则就错过大好商机，要遗憾终生的！参考资料： Novartis makes a $1B radiopharma deal, buying Mariana Oncology Novartis enters agreement to acquire Mariana Oncology, strengthening radioligand therapy pipeline（诺华官网） Mariana Oncology官网内容来源于网络，如有侵权，请联系删除。

并购抗体药物偶联物放射疗法上市批准多肽偶联药物

2024-05-02

·药明康德

超17亿美元并购！诺华加码布局核药；2亿美元助力RAS精准疗法开发……

▎药明康德内容团队编辑诺华超17亿美元收购Mariana Oncology，扩展放射性配体疗法管线诺华（Novartis）公司今日宣布，已与Mariana Oncology公司达成收购协议。Mariana Oncology是一家处于临床前阶段的生物技术公司，专注于开发新型放射性配体疗法（RLT），此次收购增强了诺华的RLT研发管线，并扩展了公司的研究基础设施和临床供应能力。根据协议，诺华将支付10亿美元前期付款，并可能再支付7.5亿美元里程碑付款。该收购包括一系列从苗头化合物优化到早期开发的RLT项目，涵盖多种实体瘤适应症，如乳腺癌、前列腺癌和肺癌。其中包括正在针对小细胞肺癌进行研究的候选药物MC-339，这是一种基于锕的RLT。RLT是诺华的重点开发技术平台之一，该公司目前拥有两款获批的RLT疗法，其中，Lutathera（Lu 177 dotatate）近日获批扩展适应症，用于治疗12岁及以上的生长抑素受体阳性（SSTR+）胃肠胰神经内分泌肿瘤（GEP-NET）的儿童患者，其中包括前肠、中肠和后肠神经内分泌肿瘤。诺华近日还与PeptiDream公司扩展研发合作，发现和优化创新大环肽。这些大环肽可能用于与放射性配体偶联。BridgeBio推出精准抗癌疗法公司，专注于RAS靶向药物开发BridgeBio Pharma公司宣布拆分旗下肿瘤学药物研发部，成立BridgeBio Oncology Therapeutics（BBOT）公司。BBOT公司同时获得2亿美元投资。BBOT最初将致力于推动3款针对RAS的癌症精准疗法，分别为：BBO-8520：一款可与KRAS G12C突变体的激活构象和失活构象结合的抑制剂。它目前正在1期临床试验中用于治疗携带KRAS G12C突变的非小细胞肺癌患者。BBO-10203：一款PI3Ka信号通路抑制剂，通过阻断RAS和PI3Ka的相互作用，抑制PI3Ka/AKT下游信号传导。BBOT计划在今年第二季度递交IND申请。BBO-11818：一款泛KRAS抑制剂，可靶向多种KRAS G12X突变体的激活状态和失活状态，预计在2025年初递交IND申请。开辟“激活致死”全新抗癌策略，新锐完成6700万美元A轮融资Delphia Therapeutics公司今日正式亮相并宣布完成6700万美元A轮融资。获得资金将用于基于创新的激活致死（activation lethality）原理，开发具有高度差异性的潜在“first-in-class”靶向抗癌疗法。它们可能具有显著抗癌活性并且为多种常见癌症患者提供持久获益。Delphia的科学创始人发现，很多致癌基因的信号通路对过度激活格外敏感。致癌基因的过度激活会导致细胞的应激通路不堪重负，最终携带这些突变的癌细胞选择性死亡。这些弱点为靶向特定调节节点，驱动信号通路过度激活而选择性杀伤肿瘤细胞提供了机会。Delphia的新一代药物开发平台整合肿瘤遗传学等先进技术，发现驱动激活致死的靶点，并开发潜在“first-in-class”疗法。开发产后抑郁致幻剂疗法，新锐完成1.03亿美元A轮融资Reunion Neuroscience公司宣布完成1.03亿美元A轮融资。获得资金将用于支持其在研疗法RE104的2期临床试验，用于治疗产后抑郁症（PPD），并扩展针对其它具有显著未满足需求的心理疾病的开发。该公司的主打疗法RE104是一款潜在“best-in-class”的4-OH-DiPT前药，靶向血清素2A受体（5HT2AR）。RE104是一种致幻化合物，在1期临床试验中，它的致幻活性与裸盖菇素（psilocybin）相似，但持续时间只有3-4小时，并且表现出与裸盖菇素类似的安全性特征。Reunion计划在本季度开始2期临床试验RECONNECT的患者注册。这项随机双盲，含活性对照的研究将评估RE104治疗中重度产后抑郁患者的疗效和安全性。▲欲了解更多前沿技术在生物医药产业中的应用，请长按扫描上方二维码，即可访问“药明直播间”，观看相关话题的直播讨论与精彩回放参考资料：[1] Novartis enters agreement to acquire Mariana Oncology, strengthening radioligand therapy pipeline. Retrieved May 2, 2024, from https://www.novartis.com/news/media-releases/novartis-enters-agreement-acquire-mariana-oncology-strengthening-radioligand-therapy-pipeline[2] BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) with $200M of private external capital to accelerate the development of its novel precision oncology pipeline. Retrieved May 2, 2024, from https://bridgebio.com/news/bridgebio-launches-bridgebio-oncology-therapeutics-bbot-with-200m-of-private-external-capital-to-accelerate-the-development-of-its-novel-precision-oncology-pipeline/[3] Delphia Therapeutics Launches to Pioneer a New Field of Cancer Medicines: Activation Lethality. Retrieved May 2, 2024, from https://www.delphiatx.com/news/delphia-therapeutics-launches-to-pioneer-a-new-field-of-cancer-medicines-activation-lethality/[4] Reunion Neuroscience Inc. Announces $103 Million Series A Financing Co-Led by MPM BioImpact and Novo Holdings. Retrieved May 2, 2024, from https://reunionneuro.com/2024/05/02/reunion-neuroscience-inc-announces-103-million-series-a-financing-co-led-by-mpm-bioimpact-and-novo-holdings/免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，聚焦全球生物医药健康创新

临床1期临床申请并购

2024-05-02

·医药魔方Pro

17.5亿美元！诺华收购核药公司Mariana Oncology

5月2日，诺华宣布收购Mariana Oncology，以加强放射性配体疗法（radioligand therapies，RLTs）的布局。根据协议条款，诺华将支付10亿美元预付款，并在完成预定里程碑后再支付7.5亿美元。此次收购涵盖了一个强大的RLT项目组合，涉及一系列实体瘤适应症（如乳腺癌、前列腺癌和肺癌），包括针对小细胞肺癌的基于锕的先导RLT项目MC-339。Mariana Oncology成立于2021年，致力于开发基于肽的靶向放射性配体疗法，旨在最大限度地提高肿瘤渗透，同时最大限度地降低毒性。Mariana 于2021年12月宣布完成7500万美元A轮融资（投资者包括Atlas Venture、Access Biotechnology 和RA Capital Management），2023年9月完成了1.75亿美元B轮融资。诺华生物医学研究总裁Fiona Marshall表示：“收购Mariana Oncology将加强诺华在放射性配体疗法（RLT）领域的领导地位。我们很高兴与Mariana合作，为癌症患者推出下一代RLT，并共同塑造RLT作为肿瘤治疗支柱的未来。”RLT是一类放射性药物，将肿瘤靶向分子（配体）与治疗性放射性同位素（放射性粒子）结合起来。RLT与特定类型肿瘤表面表达的特定受体结合。一旦与目标细胞结合，治疗性放射性同位素会导致DNA损伤，从而抑制细胞生长和复制，并可能引发细胞死亡。这种靶向途径可以将辐射递送到肿瘤，同时限制对周围细胞的损害。诺华是核药赛道当之无愧的“王者”，目前手握Lutathera和Pluvicto两款明星产品（两款产品均为收购获得），且有包括177Lu-FAP-2286、177Lu-NeoB、225Ac-PSMA-617在内的多款在研RLT产品。值得一提的是，过去几年，诺华在核药赛道的BD战略依然出众，2021年以来，通过多项合作，获得多款RLT候选药物和研发平台。以2023年为例，3月，诺华宣布与Bicycle Therapeutics达成17.5亿美元合作，开发基于双环肽的放射性偶联药物（Bicycle® Radio-Conjugates）；4月，诺华又与3B Pharmaceuticals达成4.65亿美元合作，获得其FAP靶向肽技术（包括FAP-2286）治疗和成像应用的全球权益。不难看出，在BD方面的不断深入，是诺华应对当前核药赛道激烈竞争，巩固其核药赛道领导者地位的关键策略。参考资料：[1]https://www.novartis.com/news/media-releases/novartis-enters-agreement-acquire-mariana-oncology-strengthening-radioligand-therapy-pipeline[2] https://www.marianaoncology.com/our-science/推荐阅读蛋白降解技术盘点：LYTAC、ATAC、AbTAC、PROTAB、REULR、KineTAC、IFLD……里程碑！首个Prime Editing基因编辑疗法获批临床Copyright © 2024 PHARMCUBE. All Rights Reserved.欢迎转发分享及合理引用，引用时请在显要位置标明文章来源；如需转载，请给微信公众号后台留言或发送消息，并注明公众号名称及ID。免责申明：本微信文章中的信息仅供一般参考之用，不可直接作为决策内容，医药魔方不对任何主体因使用本文内容而导致的任何损失承担责任。

并购放射疗法基因疗法

100 项与 (177镥)镥氧奥曲肽相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	V10XX04	DB13985

研发状态

适应症	最高研发状态	国家/地区	公司
神经内分泌肿瘤	批准上市	以色列更多	Advanced Accelerator Applications (UK & Ireland) Ltd. 更多
胃肠胰神经内分泌肿瘤	批准上市	美国更多	Advanced Accelerator Applications USA, Inc. 更多
Somatostatin Receptor-Positive Neuroendocrine Tumor	临床3期	中国更多	北京先通国际医药科技股份有限公司更多
嗜铬细胞瘤	临床2期	西班牙更多	Advanced Accelerator Applications SA 更多
大肠类癌	无进展	意大利更多	Advanced Accelerator Applications SA 更多

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03972488 (NETTER-2, ASCO_GI2024) 人工标引	临床3期	胃肠胰神经内分泌肿瘤一线	226	[177Lu]Lu-DOTA-TATE+octreotide long-acting release	衊齋遞鹹鹹顧觸衊鹹選(製鏇積繭蓋鹽艱壓壓壓) = 廠膚淵鏇醖網鏇夢鑰鹽積遞淵艱繭廠蓋獵襯鑰 (襯獵齋鑰廠獵齋糧網窪, 19.4 ~ NR) 更多	积极	2024-01-18
NCT03972488 (NETTER-2, ASCO_GI2024) 人工标引	临床3期	胃肠胰神经内分泌肿瘤一线	226	High-dose octreotide LAR	衊齋遞鹹鹹顧觸衊鹹選(製鏇積繭蓋鹽艱壓壓壓) = 鏇顧築鹹願鏇醖範窪鹹積遞淵艱繭廠蓋獵襯鑰 (襯獵齋鑰廠獵齋糧網窪, 7.7 ~ 13.8) 更多	积极	2024-01-18
NCT04385992 (NeoLuPaNET, ESMO2023) 人工标引	临床2期	神经内分泌肿瘤新辅助	29	PRRT + 177Lu-DOTATATE	遞膚願選築鹹遞鏇範願(範醖遞鏇衊鬱壓襯選夢) = 襯顧範範夢壓範鑰製憲構鑰糧鬱膚製願淵選淵 (網願遞醖構齋艱繭築壓 ) 更多	积极	2023-10-22
NCT03972488 (NETTER-2, Corporate Publications) 人工标引	临床3期	胃肠胰神经内分泌肿瘤一线 Somatostatin Receptor Positive	222	Lutathera+long-acting octreotide	鹽餘獵鬱網鏇窪壓鹽構(襯鏇壓網範構範憲鹽廠) = First line treatment with Lutathera in combination with long-acting octreotide demonstrated a significant improvement in progression-free survival (PFS) in patients with newly diagnosed somatostatin receptor (SSTR)-positive, Grade 2 and 3, advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) versus high-dose long-acting octreotide alone. 觸選網糧壓齋鹽廠蓋廠 (繭鹹鬱餘淵簾顧鏇繭選 ) 达到更多	积极	2023-09-25
NCT03972488 (NETTER-2, Corporate Publications) 人工标引	临床3期	胃肠胰神经内分泌肿瘤一线 Somatostatin Receptor Positive	222	long-acting octreotide		积极	2023-09-25
DCOG-NBL2009 (ESPE2023)	N/A	生长激素缺乏症 \| 甲状腺功能减退症	1	[177Lu]Lu-DOTATATE	窪鑰獵遞鹹鬱顧鏇憲鏇(網獵顧壓鏇繭齋襯觸醖) = As a complication of treatment she developed stage 2 chronic kidney 襯鬱選艱構艱範鏇廠淵 (壓憲選鑰鹹衊艱夢繭顧 )	不佳	2023-09-21
NCT04234568 (AACR2023) 人工标引	临床1期	胃肠胰神经内分泌肿瘤 SSTR Expression	31	triapine+Lutetium Dotatate LU-177	鑰衊鏇壓廠齋艱醖艱蓋(積襯衊簾網膚顧廠築糧) = One DLT in dose level 1, seven DLTs in dose level 2, and one grade 5 DLT in dose level 3 were observed. 鑰鹽築鑰憲壓蓋觸襯繭 (積餘構簾淵選鑰廠遞壓 ) 更多	积极	2023-04-14
AACR2023	N/A	神经内分泌肿瘤	36	lutetium 177 dotatate (Patients with clonal hematopoiesis (CH))	遞製齋選壓鹹構餘顧衊(顧簾鏇觸製夢網夢衊簾) = 窪遞壓願遞築獵糧膚獵觸觸繭醖選鬱餘壓鑰襯 (築齋顧醖簾憲網壓淵顧 )	-	2023-04-04
NCT04234568 (ASCO_GI2023) 人工标引	临床1期	SSTR阳性胃肠胰神经内分泌肿瘤 SSTR1 Expression	31	triapine+lutetium Lu-177 dotatate	淵選願齋構憲鏇衊網鹹(鬱膚醖餘遞繭顧齋齋選) = 願襯觸範鑰鹽醖壓齋鑰願窪繭鏇齋遞繭網選憲 (簾鹹願積糧願衊鏇鹹膚 ) 更多	积极	2023-01-24
ASCO_GI2023	N/A	神经内分泌肿瘤一线	36	Lutetium-177-dotatate	壓餘築蓋築獵構襯觸遞(構願範鑰鏇鬱繭選選觸) = 遞繭遞願壓繭願製餘鑰鏇憲遞艱襯鹽積廠獵鑰 (衊夢繭選鹽構憲夢夢襯, 30.5 ~ 64.9)	-	2023-01-24
OCLURANDOM (ESMO2022)	临床2期	高分化胰腺内分泌肿瘤	84	OCLU	壓構築廠齋壓醖糧艱餘(鏇觸淵選選選艱簾選鑰) = 遞鏇艱鹹艱醖壓壓窪選齋鹹廠顧鹹襯網襯廠鏇 (構廠鑰鹽窪鏇廠積選餘 ) 更多	积极	2022-09-12
OCLURANDOM (ESMO2022)	临床2期	高分化胰腺内分泌肿瘤	84	sunitinib (SUN)	壓構築廠齋壓醖糧艱餘(鏇觸淵選選選艱簾選鑰) = 鏇糧願顧鬱鹹鹹鏇夢膚齋鹹廠顧鹹襯網襯廠鏇 (構廠鑰鹽窪鏇廠積選餘 ) 更多	积极	2022-09-12
ACTRN12615000909527 (CONTROL NET, ASCO2022) 人工标引	临床2期	神经内分泌肿瘤	75	mNETS (177Lu-DOTATATE+capecitabine+temozolomide)	獵壓築遞觸醖獵鬱餘窪(餘窪構鏇選壓築顧衊糧) = 鑰觸糧鏇顧蓋窪艱鹹繭製繭製簾鬱遞願範積膚 (繭衊獵衊築艱構壓憲鹹, 73.1 ~ 96.8) 更多	积极	2022-06-02
ACTRN12615000909527 (CONTROL NET, ASCO2022) 人工标引	临床2期	神经内分泌肿瘤	75	177Lu-DOTATATE (mNETs)	獵壓築遞觸醖獵鬱餘窪(餘窪構鏇選壓築顧衊糧) = 憲構鏇壓壓醖淵築衊鏇製繭製簾鬱遞願範積膚 (繭衊獵衊築艱構壓憲鹹, 56.6 ~ 98.9) 更多	积极	2022-06-02